Sign up Australia
Proactive Investors - Run By Investors For Investors

Cann Group secures license to import/export medicinal cannabis products

Planning to import medicinal cannabis products for supply to Australian patients.
cannabis leaves
Cann is working with Canadian companies

Cann Group Ltd (ASX:CAN) has been granted a licence to import and export cannabis genetics and medicinal cannabis products by the Office of Drug Control, Australian Department of Health.

As a holder of this licence, the company can now apply for a permit to export raw cannabis material and cannabis oil for analytical testing.

Cann intends to utilise the analytical services of Anandia Laboratories in Canada to complement the capabilities available to the company in Australia.

The licence also allows Cann to apply for a permit to import cannabis genetics and medicinal cannabis products from legal international sources.

Cann is working closely with Canadian companies Aurora Cannabis and Anandia Laboratories to identify suitable genetics and medicinal cannabis products for inclusion in an import permit application.

The company is aiming to submit the application soon to facilitate the process of obtaining export approvals with Health Canada.

The granting of the new licence is an important milestone for Cann in building a genetic database of locally and internationally sourced cannabis strains for cultivation under its medicinal cannabis licence.

Similarly, the import/export licence is a key step in the company’s plans to import medicinal cannabis products for supply to Australian patients to complement locally manufactured products.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full CAN profile View Profile

Cann Group Ltd Timeline

Related Articles

bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
pills
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use